Concrete Ventures - Atlantic Canadian Pre-Seed Venture Capital Fund
HOME - LongShot Capital
Description: The most comfortable experience for sleep apnea patients — powered by revolutionary AI. cMAP™ is a platform software that uses artificial intelligence and machine learning during PAP therapy to predict and prevent episodes of apnea before they occur.
It is estimated that 1 billion people are affected by Obstructive Sleep Apnea (OSA) with 80% undiagnosed. Continuous Positive Airway Pressure (CPAP) therapy is the current gold standard for treating OSA, but adherence to treatment is lower than 50% after the first 3 months of use. By improving adherence to CPAP therapy:
cMAP™ is a platform software that uses artificial intelligence and machine learning during PAP therapy to predict and prevent episodes of apnea before they occur. As a result, personalized therapy can be delivered via PAP machines at lower, more comfortable air pressure levels.
Learn about the benefits that increased adherence can have for your company.
Concrete Ventures - Atlantic Canadian Pre-Seed Venture Capital Fund
HOME - LongShot Capital